Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Medical impulsive therapy (MIT): the impact of 1 week of preoperative tamsulosin on deployment of 16-French ureteral access sheaths without preoperative ureteral stent placement.

Kaler KS, Safiullah S, Lama DJ, Parkhomenko E, Okhunov Z, Ko YH, Huynh L, Patel RM, Landman J, Clayman RV.

World J Urol. 2018 May 25. doi: 10.1007/s00345-018-2336-1. [Epub ahead of print]

PMID:
29802428
2.

The HK2 Dependent "Warburg Effect" and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate.

Lis P, Dyląg M, Niedźwiecka K, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Molecules. 2016 Dec 15;21(12). pii: E1730. Review.

3.

Glutathione may have implications in the design of 3-bromopyruvate treatment protocols for both fungal and algal infections as well as multiple myeloma.

Niedźwiecka K, Dyląg M, Augustyniak D, Majkowska-Skrobek G, Cal-Bąkowska M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Oncotarget. 2016 Oct 4;7(40):65614-65626. doi: 10.18632/oncotarget.11592.

4.

Screening the yeast genome for energetic metabolism pathways involved in a phenotypic response to the anti-cancer agent 3-bromopyruvate.

Lis P, Jurkiewicz P, Cal-Bąkowska M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Oncotarget. 2016 Mar 1;7(9):10153-73. doi: 10.18632/oncotarget.7174.

5.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

6.

Dysregulated metabolism contributes to oncogenesis.

Hirschey MD, DeBerardinis RJ, Diehl AME, Drew JE, Frezza C, Green MF, Jones LW, Ko YH, Le A, Lea MA, Locasale JW, Longo VD, Lyssiotis CA, McDonnell E, Mehrmohamadi M, Michelotti G, Muralidhar V, Murphy MP, Pedersen PL, Poore B, Raffaghello L, Rathmell JC, Sivanand S, Vander Heiden MG, Wellen KE; Target Validation Team.

Semin Cancer Biol. 2015 Dec;35 Suppl:S129-S150. doi: 10.1016/j.semcancer.2015.10.002. Epub 2015 Oct 8. Review.

7.

Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy.

Majkowska-Skrobek G, Augustyniak D, Lis P, Bartkowiak A, Gonchar M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Anticancer Drugs. 2014 Jul;25(6):673-82. doi: 10.1097/CAD.0000000000000094.

PMID:
24557015
8.

Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders.

Park S, Ko YH.

J Dermatol. 2014 Jan;41(1):29-39. doi: 10.1111/1346-8138.12322. Review.

PMID:
24438142
9.

3-Bromopyruvate: a novel antifungal agent against the human pathogen Cryptococcus neoformans.

Dyląg M, Lis P, Niedźwiecka K, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Biochem Biophys Res Commun. 2013 May 3;434(2):322-7. doi: 10.1016/j.bbrc.2013.02.125. Epub 2013 Mar 26.

PMID:
23541578
10.

Cavernosal nerve preservation during robot-assisted radical prostatectomy is a graded rather than an all-or-none phenomenon: objective demonstration by assessment of residual nerve tissue on surgical specimens.

Schatloff O, Chauhan S, Kameh D, Valero R, Ko YH, Sivaraman A, Coelho RF, Marquinez J, Palmer KJ, Patel VR.

Urology. 2012 Mar;79(3):596-600. doi: 10.1016/j.urology.2011.11.029.

PMID:
22386406
11.

Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae.

Lis P, Zarzycki M, Ko YH, Casal M, Pedersen PL, Goffeau A, Ułaszewski S.

J Bioenerg Biomembr. 2012 Feb;44(1):155-61. doi: 10.1007/s10863-012-9421-8. Epub 2012 Feb 23.

PMID:
22359102
12.

Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate.

Queirós O, Preto A, Pacheco A, Pinheiro C, Azevedo-Silva J, Moreira R, Pedro M, Ko YH, Pedersen PL, Baltazar F, Casal M.

J Bioenerg Biomembr. 2012 Feb;44(1):141-53. doi: 10.1007/s10863-012-9418-3. Epub 2012 Feb 17.

PMID:
22350013
13.

Mitochondrial ATP synthase catalytic mechanism: a novel visual comparative structural approach emphasizes pivotal roles for Mg²⁺ and P-loop residues in making ATP.

Blum DJ, Ko YH, Pedersen PL.

Biochemistry. 2012 Feb 21;51(7):1532-46. doi: 10.1021/bi201595v. Epub 2012 Feb 9.

PMID:
22243519
14.

Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potential.

Chen YB, Aon MA, Hsu YT, Soane L, Teng X, McCaffery JM, Cheng WC, Qi B, Li H, Alavian KN, Dayhoff-Brannigan M, Zou S, Pineda FJ, O'Rourke B, Ko YH, Pedersen PL, Kaczmarek LK, Jonas EA, Hardwick JM.

J Cell Biol. 2011 Oct 17;195(2):263-76. doi: 10.1083/jcb.201108059. Epub 2011 Oct 10.

15.

Critical review of 'pentafecta' outcomes after robot-assisted laparoscopic prostatectomy in high-volume centres.

Patel VR, Abdul-Muhsin HM, Schatloff O, Coelho RF, Valero R, Ko YH, Sivaraman A, Palmer KJ, Chauhan S.

BJU Int. 2011 Sep;108(6 Pt 2):1007-17. doi: 10.1111/j.1464-410X.2011.10521.x. Review.

16.

The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies.

Mathupala SP, Ko YH, Pedersen PL.

Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):1225-30. doi: 10.1016/j.bbabio.2010.03.025. Epub 2010 Apr 8. Review.

17.

Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.

Mathupala SP, Ko YH, Pedersen PL.

Semin Cancer Biol. 2009 Feb;19(1):17-24. doi: 10.1016/j.semcancer.2008.11.006. Epub 2008 Dec 3. Review.

18.

Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma.

Kim WS, Park YH, Lee SH, Ryoo BY, Yang SH, Lee SS, Kim MS, Kim K, Park KW, Im DH, Kang JH, Lee J, Ko YH, Ahn YC, Lim DH, Park K, Bang SM.

Med Oncol. 2008;25(4):447-50. doi: 10.1007/s12032-008-9065-z. Epub 2008 Apr 23.

PMID:
18431552
19.

Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD.

Ohshima K, Kimura H, Yoshino T, Kim CW, Ko YH, Lee SS, Peh SC, Chan JK; CAEBV Study Group.

Pathol Int. 2008 Apr;58(4):209-17. doi: 10.1111/j.1440-1827.2008.02213.x. Review.

PMID:
18324913
20.

Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma.

Park BB, Ryoo BY, Lee JH, Kwon HC, Yang SH, Kang HJ, Kim HJ, Oh SY, Ko YH, Huh JR, Lee SS, Nam EM, Park KW, Kim JH, Kang JH, Bang SM, Park S, Kim K, Park K, Suh C, Kim WS.

Leuk Lymphoma. 2007 Apr;48(4):716-22.

PMID:
17454629

Supplemental Content

Loading ...
Support Center